MAGEC2 and non-small cell lung carcinoma: The BI 1361849 mRNA vaccine, comprising MUC1, survivin, NY-ESO-1, 5T4, MAGE-C1, and MAGE-C2, was intradermally injected into metastatic NSCLC patients (NCT03164772, phase I/II).